NASDAQ:KLTOW Klotho Neurosciences (KLTOW) Stock Price, News & Analysis $0.22 +0.00 (+1.90%) As of 03:43 PM Eastern Add Share Share Stock Analysis Stock AnalysisChartSEC FilingsTrendsBuy This Stock About Klotho Neurosciences Stock (NASDAQ:KLTOW) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Klotho Neurosciences alerts:Sign Up Key Stats Today's Range$0.21▼$0.2350-Day Range$0.02▼$0.6652-Week Range$0.01▼$0.95Volume11,202 shsAverage Volume194,622 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Klotho Neurosciences is a clinical-stage biopharmaceutical company focused on harnessing the biology of the Klotho protein to develop treatments for age-related disorders. The company’s research platform is designed to identify and advance therapeutic candidates—ranging from small molecules and peptides to gene therapy vectors—that upregulate or otherwise modulate Klotho expression. By targeting a protein implicated in neuroprotection, metabolic regulation and tissue homeostasis, the company seeks to address a broad array of neurodegenerative and systemic conditions. The company’s pipeline includes early-stage programs aimed at enhancing Klotho activity in the central nervous system, with lead assets under evaluation for indications such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and vascular cognitive impairment. These programs leverage a combination of proprietary gene delivery systems, receptor agonists and Klotho gene enhancers discovered through in-house screening efforts and strategic partnerships. Preclinical data have demonstrated improved neuronal survival, reduced inflammation and enhanced synaptic function in animal models. Founded out of academic research into the aging process, Klotho Neurosciences trades on the Nasdaq under the symbol KLTOW. Headquartered in the United States, the company collaborates with academic institutions, contract research organizations and biotechnology partners to advance its pipeline. Its leadership team comprises executives and scientists with backgrounds in neurology, gene therapy and drug discovery, all united by a goal of translating foundational insights about the Klotho protein into novel, disease-modifying therapies.AI Generated. May Contain Errors. Read More Receive KLTOW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Klotho Neurosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address KLTOW Stock News HeadlinesKlotho Neurosciences Stock Jumps As FDA Grants Orphan Drug Tag To ALS Gene TherapyJuly 11, 2025 | msn.comKLTOW Klotho Neurosciences, Inc. WT EXP 062129June 11, 2025 | seekingalpha.comSee More Headlines KLTOW Stock Analysis - Frequently Asked Questions How have KLTOW shares performed this year? Klotho Neurosciences' stock was trading at $0.0462 at the beginning of the year. Since then, KLTOW shares have increased by 365.4% and is now trading at $0.2150. How do I buy shares of Klotho Neurosciences? Shares of KLTOW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry N/A Sub-IndustryN/A Current SymbolNASDAQ:KLTOW CIK1907223 WebN/A PhoneN/AFaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableN/A BetaN/A Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:KLTOW) was last updated on 7/28/2025 by MarketBeat.com Staff From Our PartnersAI Frenzy Could Send ‘EarnPhone’ SoaringThe hidden fuel behind AI? Your phone. Billions of data points — from your clicks, swipes, scrolls, and sea...Mode Mobile | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredIs America’s Everything Bubble About to Burst?On July 4th, Trump signed the “One Big Beautiful Bill,” adding $3.4 trillion to the national debt — and pushin...American Alternative | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTop 10 Green Zone Stocks to Buy NowOthers have paid $2,000 for access to stock picks like these—this weekend, you can get them free. Using a p...TradeSmith | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredOne stock to replace NvidiaInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Klotho Neurosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Klotho Neurosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.